S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma: final results of the randomized AIO MATEO phase II trial
Purpose - Platinum-fluoropyrimidine combinations are standard of care for treatment of metastatic esophagogastric adenocarcinoma. The optimal duration of first-line chemotherapy is unknown, however, and maintenance strategies have not yet been established. - Design - MATEO is an international random...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2 June 2023
|
| In: |
ESMO open
Year: 2023, Jahrgang: 8, Heft: 3, Pages: 1-9 |
| ISSN: | 2059-7029 |
| DOI: | 10.1016/j.esmoop.2023.101572 |
| Online-Zugang: | Resolving-System, kostenfrei: https://doi.org/10.1016/j.esmoop.2023.101572 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S2059702923008037 
|
| Verfasserangaben: | G. Stocker, S. Lorenzen, T. Ettrich, A.-L. Herz, F. Longo, A. Kiani, M. Venerito, J. Trojan, R. Mahlberg, N. Moosmann, B. Chibaudel, S. Kubicka, R. Greil, S. Daum, M. Geissler, J. Larcher-Senn, G. Keller, F. Lordick & G.M. Haag |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1860841252 | ||
| 003 | DE-627 | ||
| 005 | 20240329080812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231006s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2023.101572 |2 doi | |
| 035 | |a (DE-627)1860841252 | ||
| 035 | |a (DE-599)KXP1860841252 | ||
| 035 | |a (OCoLC)1425210548 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Stocker, Gertraud |e VerfasserIn |0 (DE-588)1305063767 |0 (DE-627)186084183X |4 aut | |
| 245 | 1 | 0 | |a S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma |b final results of the randomized AIO MATEO phase II trial |c G. Stocker, S. Lorenzen, T. Ettrich, A.-L. Herz, F. Longo, A. Kiani, M. Venerito, J. Trojan, R. Mahlberg, N. Moosmann, B. Chibaudel, S. Kubicka, R. Greil, S. Daum, M. Geissler, J. Larcher-Senn, G. Keller, F. Lordick & G.M. Haag |
| 264 | 1 | |c 2 June 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Interim results of this trial have been presented at ESMO Congress 2020 and DGHO Congress 2020 | ||
| 500 | |a Gesehen am 06.10.2023 | ||
| 520 | |a Purpose - Platinum-fluoropyrimidine combinations are standard of care for treatment of metastatic esophagogastric adenocarcinoma. The optimal duration of first-line chemotherapy is unknown, however, and maintenance strategies have not yet been established. - Design - MATEO is an international randomized phase II trial exploring efficacy and safety of S-1 maintenance therapy in human epidermal growth factor receptor 2 (HER2)-negative advanced esophagogastric adenocarcinoma. After 3 months of first-line platinum-fluoropyrimidine-based induction therapy, patients without progression were randomized in a 2 : 1 allocation to receive S-1 monotherapy (arm A) or to continue combination chemotherapy (arm B). The primary objective was to show non-inferiority of overall survival in the S-1 maintenance group. Progression-free survival, adverse events, and quality of life were secondary endpoints. - Results - From 2014 to 2019, 110 and 55 patients were randomized in arm A and arm B, respectively (recruitment closed prematurely). Median overall survival from randomization was 13.4 months for arm A and 11.4 months for arm B [hazard ratio 0.97 (80% confidence interval 0.76-1.23), P = 0.86]. Median progression-free survival from randomization was 4.3 and 6.1 months for arm A versus arm B, respectively [hazard ratio 1.10 (80% confidence interval 0.86-1.39), P = 0.62]. Patients in arm A had numerically fewer treatment-related adverse events (84.9% versus 93.9%) and significantly less peripheral sensory polyneuropathy ≥grade 2 (9.4% versus 36.7%). - Conclusions - S-1 maintenance following platinum-based induction therapy leads to non-inferior survival outcomes compared with the continuation of platinum-based combination. Toxicity patterns favor a fluoropyrimidine maintenance strategy. These data challenge the continued use of platinum combination chemotherapy after response to 3 months induction therapy in patients with advanced human epidermal growth factor receptor 2-negative esophagogastric adenocarcinoma. | ||
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a esophageal cancer | |
| 650 | 4 | |a esophagogastric adenocarcinoma | |
| 650 | 4 | |a gastric cancer | |
| 650 | 4 | |a maintenance | |
| 650 | 4 | |a S-1 | |
| 700 | 1 | |a Lorenzen, Sylvie |d 1973- |e VerfasserIn |0 (DE-588)128891106 |0 (DE-627)384629202 |0 (DE-576)297385739 |4 aut | |
| 700 | 1 | |a Ettrich, Thomas J. |e VerfasserIn |0 (DE-588)133859584 |0 (DE-627)557788226 |0 (DE-576)300153031 |4 aut | |
| 700 | 1 | |a Herz, Anne-Lina |e VerfasserIn |4 aut | |
| 700 | 1 | |a Longo, Federico |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kiani, Alexander |e VerfasserIn |0 (DE-588)1124425195 |0 (DE-627)878114858 |0 (DE-576)482519711 |4 aut | |
| 700 | 1 | |a Venerito, Marino |d 1975- |e VerfasserIn |0 (DE-588)143142216 |0 (DE-627)64282603X |0 (DE-576)335285066 |4 aut | |
| 700 | 1 | |a Trojan, Jörg |d 1969- |e VerfasserIn |0 (DE-588)120162075 |0 (DE-627)696434393 |0 (DE-576)292072120 |4 aut | |
| 700 | 1 | |a Mahlberg, Rolf |d 1959- |e VerfasserIn |0 (DE-588)112117856 |0 (DE-627)476592305 |0 (DE-576)289721911 |4 aut | |
| 700 | 1 | |a Moosmann, Nicolas |d 1974- |e VerfasserIn |0 (DE-588)124297684 |0 (DE-627)085769002 |0 (DE-576)185350534 |4 aut | |
| 700 | 1 | |a Chibaudel, Benoist |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kubicka, Stefan |e VerfasserIn |0 (DE-588)130338052 |0 (DE-627)498009602 |0 (DE-576)298135574 |4 aut | |
| 700 | 1 | |a Greil, Richard |d 1957- |e VerfasserIn |0 (DE-588)133878546 |0 (DE-627)557867495 |0 (DE-576)300166176 |4 aut | |
| 700 | 1 | |a Daum, Severin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Geißler, Michael |d 1964- |e VerfasserIn |0 (DE-588)133573222 |0 (DE-627)548763305 |0 (DE-576)299942767 |4 aut | |
| 700 | 1 | |a Larcher-Senn, Julian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Keller, Gisela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Lordick, Florian |d 1966- |e VerfasserIn |0 (DE-588)114389349 |0 (DE-627)52295085X |0 (DE-576)289795567 |4 aut | |
| 700 | 1 | |a Haag, Georg Martin |d 1979- |e VerfasserIn |0 (DE-588)133390934 |0 (DE-627)544043863 |0 (DE-576)29981548X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d [London] : Elsevier, 2016 |g 8(2023), 3 vom: Juni, Artikel-ID 101572, Seite 1-9 |h Online-Ressource |w (DE-627)84705344X |w (DE-600)2844985-X |w (DE-576)454658516 |x 2059-7029 |7 nnas |a S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma final results of the randomized AIO MATEO phase II trial |
| 773 | 1 | 8 | |g volume:8 |g year:2023 |g number:3 |g month:06 |g elocationid:101572 |g pages:1-9 |g extent:9 |a S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma final results of the randomized AIO MATEO phase II trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.esmoop.2023.101572 |x Resolving-System |z kostenfrei |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2059702923008037 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20231006 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 133390934 |a Haag, Georg Martin |m 133390934:Haag, Georg Martin |d 910000 |d 910100 |d 50000 |e 910000PH133390934 |e 910100PH133390934 |e 50000PH133390934 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 19 |y j | ||
| 998 | |g 114389349 |a Lordick, Florian |m 114389349:Lordick, Florian |d 50000 |e 50000PL114389349 |k 0/50000/ |p 18 | ||
| 999 | |a KXP-PPN1860841252 |e 4381728327 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1860841252"],"doi":["10.1016/j.esmoop.2023.101572"]},"origin":[{"dateIssuedDisp":"2 June 2023","dateIssuedKey":"2023"}],"name":{"displayForm":["G. Stocker, S. Lorenzen, T. Ettrich, A.-L. Herz, F. Longo, A. Kiani, M. Venerito, J. Trojan, R. Mahlberg, N. Moosmann, B. Chibaudel, S. Kubicka, R. Greil, S. Daum, M. Geissler, J. Larcher-Senn, G. Keller, F. Lordick & G.M. Haag"]},"relHost":[{"name":{"displayForm":["European Society for Medical Oncology"]},"origin":[{"dateIssuedDisp":"2016-","publisher":"Elsevier ; BMJ","dateIssuedKey":"2016","publisherPlace":"[London] ; London"}],"id":{"zdb":["2844985-X"],"eki":["84705344X"],"issn":["2059-7029"]},"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"cancer horizons","title":"ESMO open","title_sort":"ESMO open"}],"note":["Gesehen am 13.06.24"],"disp":"S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma final results of the randomized AIO MATEO phase II trialESMO open","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"84705344X","language":["eng"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"European Society for Medical Oncology"}],"pubHistory":["1.2016 -"],"part":{"year":"2023","issue":"3","pages":"1-9","text":"8(2023), 3 vom: Juni, Artikel-ID 101572, Seite 1-9","volume":"8","extent":"9"}}],"physDesc":[{"extent":"9 S."}],"title":[{"title_sort":"S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma","subtitle":"final results of the randomized AIO MATEO phase II trial","title":"S-1 maintenance therapy in Caucasian patients with metastatic esophagogastric adenocarcinoma"}],"person":[{"family":"Stocker","given":"Gertraud","roleDisplay":"VerfasserIn","display":"Stocker, Gertraud","role":"aut"},{"family":"Lorenzen","given":"Sylvie","display":"Lorenzen, Sylvie","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Ettrich","given":"Thomas J.","roleDisplay":"VerfasserIn","display":"Ettrich, Thomas J.","role":"aut"},{"display":"Herz, Anne-Lina","roleDisplay":"VerfasserIn","role":"aut","family":"Herz","given":"Anne-Lina"},{"roleDisplay":"VerfasserIn","display":"Longo, Federico","role":"aut","family":"Longo","given":"Federico"},{"family":"Kiani","given":"Alexander","display":"Kiani, Alexander","roleDisplay":"VerfasserIn","role":"aut"},{"roleDisplay":"VerfasserIn","display":"Venerito, Marino","role":"aut","family":"Venerito","given":"Marino"},{"family":"Trojan","given":"Jörg","roleDisplay":"VerfasserIn","display":"Trojan, Jörg","role":"aut"},{"given":"Rolf","family":"Mahlberg","role":"aut","roleDisplay":"VerfasserIn","display":"Mahlberg, Rolf"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Moosmann, Nicolas","given":"Nicolas","family":"Moosmann"},{"given":"Benoist","family":"Chibaudel","role":"aut","display":"Chibaudel, Benoist","roleDisplay":"VerfasserIn"},{"display":"Kubicka, Stefan","roleDisplay":"VerfasserIn","role":"aut","family":"Kubicka","given":"Stefan"},{"roleDisplay":"VerfasserIn","display":"Greil, Richard","role":"aut","family":"Greil","given":"Richard"},{"roleDisplay":"VerfasserIn","display":"Daum, Severin","role":"aut","family":"Daum","given":"Severin"},{"roleDisplay":"VerfasserIn","display":"Geißler, Michael","role":"aut","family":"Geißler","given":"Michael"},{"display":"Larcher-Senn, Julian","roleDisplay":"VerfasserIn","role":"aut","family":"Larcher-Senn","given":"Julian"},{"role":"aut","display":"Keller, Gisela","roleDisplay":"VerfasserIn","given":"Gisela","family":"Keller"},{"given":"Florian","family":"Lordick","role":"aut","display":"Lordick, Florian","roleDisplay":"VerfasserIn"},{"display":"Haag, Georg Martin","roleDisplay":"VerfasserIn","role":"aut","family":"Haag","given":"Georg Martin"}],"language":["eng"],"recId":"1860841252","type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Interim results of this trial have been presented at ESMO Congress 2020 and DGHO Congress 2020","Gesehen am 06.10.2023"]} | ||
| SRT | |a STOCKERGERS1MAINTENA2202 | ||